| Similar Articles |
|---|
 |
The Motley Fool
September 12, 2005
M.D. Mitchell |
Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch.   |
The Motley Fool
December 29, 2006
Brian Lawler |
Lilly's Patents Stay in Bloom Even with upcoming patent expiries, Lilly isn't in nearly the same desperate situation that some of its large-cap pharma peers will be dealing with in the upcoming years. Investors, take note. |
Chemistry World
September 11, 2012
Maria Burke |
Orphan drugs set for 'tremendous growth' A new report by Thomson Reuters offers clear confirmation that developing drugs for rare, or orphan, diseases is economically attractive, despite the smaller patient pool. |
Chemistry World
August 23, 2012
Simon Campbell |
Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth. |
Pharmaceutical Executive
October 1, 2011
Jill Wechsler |
"Representing" Healthcare to the Fullest Since coming to Congress about 35 years ago, Henry Waxman, Congressional Representative from Los Angeles, California, has been pivotal in shaping legislation on health and drug regulatory issues. |
Chemistry World
February 2, 2012
Andrew Turley |
AstraZeneca to cut 7300 more jobs UK drugmaker AstraZeneca has announced plans to cut a further 7300 jobs to make annual savings of $1.6 billion by the end of 2014, a move that will cost the company $2.1 billion in the near term. |
Chemistry World
January 28, 2010
Nina Notman |
AstraZeneca's workforce slashed again Pharma giant AstraZeneca is to cut another 8,000 jobs globally over the next four years - with approximately 1,800 additional research and development staff to be lost. |
Chemistry World
March 3, 2015
Rebecca Trager |
US universities warn against patent reform proposals Legislation pending in the US Congress to address so-called patent trolling is crafted too broadly and would damage the flow of discoveries from academia to the private sector. |
Pharmaceutical Executive
June 1, 2013
Julian Upton |
Opening the Patent Box Are the answers to the UK pharma sector's problems to be found in the government's new "Patent Box," which introduces a lower rate of corporation tax on profits generated from UK-owned intellectual property. |
Chemistry World
September 11, 2014
Emma Stoye |
Pharma sales 'will reach $1 trillion' in 2014 Global sales in the pharmaceutical industry are set to go over the $1 trillion mark this year, according to a report by Thomson Reuters. |
Information Today
October 29, 2015 |
Thomson Reuters Streamlines Healthcare Industry Analysis Thomson Reuters rolled out the Healthcare Intelligence application for Thomson Reuters Eikon to improve workflow for financial professionals. |
The Motley Fool
April 10, 2007
Brian Lawler |
Barr Issues a Challenge Barr challenges the patents on one of Sanofi's top drugs. |
Pharmaceutical Executive
September 1, 2010 |
Looking Beyond the Patent Cliff Pfizer's VP and Assistant General Counsel for Global Patents and Policy, Roy Waldron, discusses its collaborative strategy to refresh the face of IP. |
Pharmaceutical Executive
January 21, 2014
Tim Powell |
Innovation: The Moneyball Test Successful innovation now has to align with key metrics of value; can an old baseball metaphor help guide the way? |
Chemistry World
June 24, 2011
Andrew Turley |
Pfizer to Keep 350 Jobs at Sandwich US drug giant Pfizer has said that it will keep 350 jobs at its site in Sandwich, UK. |
Chemistry World
January 17, 2013
Simon Hadlington |
Nanotech patent jungle set to become denser in 2013 As we welcome in 2013, will nanotechnology continue to dominate many of the scientific headlines in the coming year, just as it has done over the past decade? |
The Motley Fool
March 31, 2010
Brian Orelli |
When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies. |
Pharmaceutical Executive
August 1, 2005
Jill Wechsler |
Washington Report: Treating Patents It may seem unusual that a court ruling challenging patent protections is considered a victory for Big Pharma. But the decision was supported by pharmaceutical companies, along with the Justice Department, as a way to spur biomedical research and new-drug development. |
Chemistry World
March 4, 2013
Andy Extance |
UK considers patent rule change for trials The UK has announced plans to amend aspects of its patent law that may be encouraging pharma companies to run their clinical trials in other countries. |
Wall Street & Technology
September 19, 2006
Paul Allen |
Patent Processing For both the patent holders and potential transgressors, technology patents can be a high-stakes game in the financial world, in both monetary awards and ongoing business feasibility. |
Chemistry World
October 2006 |
Head to Head For: Patents protect inventions by giving the owner of the patent the right to stop anyone from making or using the invention without the owner's permission... Against: Patents are a menace... |
The Motley Fool
June 26, 2006
Stephen D. Simpson |
Is Novartis the Future of Generics? Merck's recent pricing action might just be the beginning of the end of generics as we know them. Investors, take note. |
Information Today
June 20, 2013 |
Thomson Innovation Acquires Full-Text Australian Patent Records Thomson Innovation, the Intellectual Property & Science business of Thomson Reuters, now includes the full text of patents from Australia: innovation (petty) and granted patents and applications. |
The Motley Fool
January 31, 2011
Brian Orelli |
Pharma Goes Back to School But will it produce more drugs? The pharmaceutical industry is headed back to school, with a number of large drugmakers announcing partnerships with universities. |
InternetNews
January 28, 2008
Stuart J. Johnston |
Microsoft: King of The Patent Hill Microsoft emerges as top tech patent holder with more than 15,000 patents pending. |
Chemistry World
October 26, 2012
Andrew Turley |
Patent woes lead to sharp sales losses Financial results for the third quarter of 2012 from several big pharma companies reveal a dramatic loss of sales as patent protection for key drugs expires. It is an all too familiar story for the industry |
Chemistry World
August 23, 2012
Dean Baker |
Monopoly money It is remarkable that the system of patent support for prescription drug research has not become more of a policy issue. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
Chemistry World
October 1, 2008
Victoria Gill |
GSK to Cut 850 R&D Jobs GlaxoSmithKline has announced that up to 850 R&D jobs will be cut as it implements its new business strategy. |
The Motley Fool
November 15, 2007
Charly Travers |
John Edwards, Frozen Caveman Lawyer Presidential hopeful John Edwards' health-care plans could destroy drug research and development in this country by removing the patent protection on breakthrough drugs. |
Chemistry World
December 11, 2007
Rebecca Trager |
Patent Delays Mar Bumper Year for US Tech Transfer Despite filing more applications than in preceding years, American universities secured fewer patents in 2006 because of delays at the US Patent and Trademark Office. |
The Motley Fool
June 20, 2011
Luke Timmerman |
Pfizer's Idea to Fix the Drug Development Crisis, Which Probably Won't Work (But Just Might) In a worst-case scenario, Pfizer flushes a few hundred million dollars down the tubes. What's the best-case scenario? |
Pharmaceutical Executive
October 1, 2010 |
Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector. |
Inc.
July 24, 2002
Jennifer A. Redmond |
Strategic Patenting What to consider when you're filing a patent and strategic decisions you'll need to make. |
The Motley Fool
January 31, 2007
Brian Lawler |
You're Only Hurting Yourself, Thailand Thailand's decision to allow generics could do more harm than good. Investors, take note. |
Pharmaceutical Executive
October 1, 2005
Brad Miles |
Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies. |
Pharmaceutical Executive
May 1, 2005
Margaret Buck |
Legal: No Exception? An important legal loophole has made patented tools available for biotech research. Today, though, it appears to be closing. |
Chemistry World
July 11, 2012 |
Europe-Wide Single Patent Stalls Again A single European patent is on the wish list of small innovative businesses. |
Information Today
May 19, 2008 |
Thomson Reuters Expands Japanese Patent Coverage in DWPI Thomson Reuters has further increased coverage of the growing patent activity in the Asia Pacific region with the addition of registered Japanese Utility Models in Derwent World Patents Index (DWPI). |
BusinessWeek
April 18, 2005
Manjeet Kripalani |
India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India. |
IEEE Spectrum
November 2006
Harry Goldstein |
Patent Power The world's most valuable patent portfolios: Boeing... Ricoh... IBM... Hitachi... etc. |
The Motley Fool
January 30, 2007
Brian Lawler |
Pfizer Fights a Generic Threat Pfizer attempts to fend off a generic threat in Canada for its top drug. It's a trial worth paying attention to for its shareholders, as Canada does represent one of the larger pharmaceutical markets in the world. |
Chemistry World
October 26, 2011
Maria Burke |
Europe risks being outstripped by R&D rivals EU companies are lagging behind in R&D investment compared with major competitors from the US and some Asian economies, according to the European Commission's 2011 EU Industrial R&D Investment Scoreboard. |
Chemistry World
March 6, 2015
Rebecca Trager |
US universities back new bill to curb patent trolls The academic research community is endorsing new legislation to clamp down on so-called patent trolling, introduced by Senator Chris Coons and several Democratic colleagues. |
Chemistry World
November 28, 2008
Matt Wilkinson |
EU claims pharma delaying tactics cost 3 billion euros Pharmaceutical manufacturers have been criticised by the EU competition commission for slowing the entry of generic medicines to the market. |
Chemistry World
November 1, 2013
Laura Howes |
UK failing to capitalize on graphene A new policy statement from the Institution of Mechanical Engineers warns that while UK universities lead the world in graphene development, the country's poor commercialization of the material could see it fall behind. |
Chemistry World
September 17, 2010
Andrew Turley |
Free trade could throttle generics from India International agreements on intellectual property threaten the flow of generic HIV drugs from India to developing countries, according to a new report. |
Pharmaceutical Executive
September 1, 2010 |
Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development. |
Chemistry World
September 10, 2015
Katrina Megget |
Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions |
Information Today
March 24, 2003
Nancy Lambert |
Thomson Opens Its Patent Store This service plans to provide a truly comprehensive patent document delivery service, with one-stop shopping for virtually all patents from any time period, anywhere in the world, and to provide it via high-speed Web access. |
